Meta-long Papyrus: Meta-analysis of mid to long-term outcomes of PK Papyrus covered stent

source extracted confidence: high 2026-04-09
#humans #chromium-alloys #coated-materials-biocompatible #coronary-artery-disease #observational-studies-as-topic

Meta-long Papyrus: Meta-analysis of mid to long-term outcomes of PK Papyrus covered stent

Jurado-Román et al., 2024 | Catheter Cardiovasc Interv | Meta Analysis

Citation

Jurado-Román Alfonso, Tébar-Márquez Daniel, ... Moreno Raúl. Meta-long Papyrus: Meta-analysis of mid to long-term outcomes of PK Papyrus covered stent. Catheter Cardiovasc Interv. 2024-Sep;104(3):492-498. doi:10.1002/ccd.31157

Abstract

BACKGROUND: Although covered stents (CS) represent a potentially life-saving intervention for coronary perforation (CAP), their application has expanded to other contexts, including coronary aneurysms (CAA). However, data regarding mid- and long-term outcomes of CS in these settings scenarios remains limited. AIMS: This meta-analysis aims to evaluate major adverse cardiac events (MACE) from discharge through long-term follow-up in patients undergoing percutaneous coronary intervention with the new generation polyurethane-covered cobalt-chromium PK Papyrus CS. METHODS: We conducted a meta-analysis of data from three observational trials that included long-term follow-up of patients who underwent PK Papyrus CS implantation: Papyrus-Spain, SOS PK Papyrus, and PAST-PERF registry. RESULTS: 332 patients underwent PK Papyrus CS implantation, 236 (71.1%) for CAP, 70 (21.1%) for CAA and 26 (7.8%) for other indications. After a mean follow-up of 16.2 months, the MACE was 14.3%, with Target Lesion Revascularization (TLR) being the most frequent (8.5%), followed by stent thrombosis (ST), 3.3% and cardiac death (CD), 2.6%. Comparing CAP and CAA subgroups, the MACE rate in CAA was significantly higher than CAP (21.4% vs 9.7%, p < 0.01), primary driven by ST (CAA: 8.6% vs CAP: 1.3%; p = 0.0015). CONCLUSIONS: The clinical outcomes following PK Papyrus CS implantation are deemed acceptable, considering the challenging scenarios and the existing alternative treatments. However, MACE rates in patients with CAA who received Papyrus PK CS were significantly higher than in those with CAP, underscoring the importance of meticulous patient selection and optimization of CS in these complex patients and coronary anatomies.

Key Findings

332 patients underwent PK Papyrus CS implantation, 236 (71.1%) for CAP, 70 (21.1%) for CAA and 26 (7.8%) for other indications. After a mean follow-up of 16.2 months, the MACE was 14.3%, with Target Lesion Revascularization (TLR) being the most frequent (8.5%), followed by stent thrombosis (ST), 3.3% and cardiac death (CD), 2.6%. Comparing CAP and CAA subgroups, the MACE rate in CAA was significantly higher than CAP (21.4% vs 9.7%, p < 0.01), primary driven by ST (CAA: 8.6% vs CAP: 1.3%; p = 0.0

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population caa who received papyrus
Sample Size 332
Age Range See abstract
Condition See abstract

MeSH Terms

  • Humans
  • Chromium Alloys
  • Coated Materials, Biocompatible
  • Coronary Artery Disease
  • Observational Studies as Topic
  • Percutaneous Coronary Intervention
  • Polyurethanes
  • Prosthesis Design
  • Risk Assessment
  • Risk Factors
  • Stents
  • Time Factors
  • Treatment Outcome

Evidence Classification

  • Level: Meta Analysis
  • Publication Types: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't
  • Vertical: chromium

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09